Abstract
Objective:
Animal studies have shown that irisin is a myokine secreted following physical exercise, and that it induces the remodeling of white adipose tissue toward brown adipose tissue. Therefore, a protective role of irisin against obesity, diabetes, and other metabolic and cardiovascular conditions has been hypothesized. However, data in humans are contradictory and few data are available concerning the general population.
Design:
We aimed to evaluate the association between serum irisin concentrations and habitual physical activity, as well as other metabolic and cardiovascular factors in a general population in a Mediterranean area.
Methods:
We considered 858 consecutive individuals included in the ABCD (Alimentazione, Benessere Cardiovascolare e Diabete) study (ISRCTN15840340), a longitudinal observational single-center study of a cohort representative of the general population of Palermo, Sicily. Irisin serum concentrations (Phoenix Europe, Germany), habitual physical activity (HPA) level, and other blood and clinical variables were measured.
Results:
The irisin serum concentrations were not normally distributed in the cohort (Shapiro-Wilk test=0.94; P<0.001). A significant association between irisin concentrations and HPA was observed (P<0.001). Irisin concentrations were higher in women than in men (P<0.01), and significantly correlated with serum concentrations of HDL-cholesterol (P<0.05) and hs-C-reactive protein (hs-CRP; P<0.05). Binary logistic regression analysis demonstrated that high (⩾ median value) irisin serum concentrations were significantly associated with female gender (OR=1.63; 95% CI=1.16–2.28), high serum hs-CRP concentrations (OR=1.61; 95% CI=1.02–2.54) and the HPA level (OR=1.42; 95% CI=1.02–1.96).
Conclusions:
Our study confirms, in a cohort of a general population, that irisin concentrations gradually increase with the usual level of habitual physical activity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hall KD, Heymsfield SB, Kemnitz JW, Klein S, Schoeller DA, Speakman JR . Energy balance and its components: implications for body weight regulation. Am J Clin Nutr 2012; 95: 989–994.
Samuel VT, Shulman GI . The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest 2016; 126: 12–22.
Caballero B . The global epidemic of obesity: an overview. Epidemiol Rev 2007; 29: 1–5.
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016; 387: 1513–1530.
Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481: 463–468.
Jedrychowski MP, Wrann CD, Paulo JA, Gerber KK, Szpyt J, Robinson MM et al. Detection and quantitation of circulating human irisin by tandem mass spectrometry. Cell Metab 2015; 22: 734–740.
Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 2013; 98: E769–E778.
Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS . Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014; 63: 207–217.
Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 2012; 61: 1725–1738.
Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF . Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—correlation with body mass index. Peptides 2013; 39: 125–130.
Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 2013; 98: 4899–4907.
Pardo M, Crujeiras AB, Amil M, Aguera Z, Jiménez-Murcia S, Baños R et al. Association of irisin with fat mass, resting energy expenditure, and daily activity in conditions of extreme body mass index. Int J Endocrinol 2014; 2014: 857270.
Sanchis-Gomar F, Alis R, Pareja-Galeano H, Sola E, Victor VM, Rocha M et al. Circulating irisin levels are not correlated with BMI, age, and other biological parameters in obese and diabetic patients. Endocrine 2014; 46: 674–677.
Al-Daghri NM, Alokail MS, Rahman S, Amer OE, Al-Attas OS, Alfawaz H et al. Habitual physical activity is associated with circulating irisin in healthy controls but not in subjects with diabetes mellitus type 2. Eur J Clin Invest 2015; 45: 775–781.
García-Fontana B, Reyes-García R, Morales-Santana S, Ávila-Rubio V, Muñoz-Garach A, Rozas-Moreno P et al. Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state? Endocrine 2016; 52: 54–62.
Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol 2014; 592: 1091–1107.
Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013; 27: 365–369.
Oelmann S, Nauck M, Völzke H, Bahls M, Friedrich N . Circulating irisin concentrations are associated with a favourable lipid profile in the general population. PLoS One 2016; 11: e0154319.
Hwang YC, Jeon WS, Park CY, Youn BS . The ratio of skeletal muscle mass to visceral fat area is a main determinant linking circulating irisin to metabolic phenotype. Cardiovasc Diabetol 2016; 15: 9.
Ebert T, Focke D, Petroff D, Wurst U, Richter J, Bachmann A et al. Serum levels of the myokine irisin in relation to metabolic and renal function. Eur J Endocrinol 2014; 170: 501–506.
Miyamoto-Mikami E, Sato K, Kurihara T, Hasegawa N, Fujie S, Fujita S et al. Endurance training-induced increase in circulating irisin levels is associated with reduction of abdominal visceral fat in middle-aged and older adults. PLoS One 2015; 10: e0120354.
Tsuchiya Y, Ando D, Takamatsu K, Goto K . Resistance exercise induces a greater irisin response than endurance exercise. Metabolism 2015; 64: 1042–1050.
Huh JY, Siopi A, Mougios V, Park KH, Mantzoros CS . Irisin in response to exercise in humans with and without metabolic syndrome. J Clin Endocrinol Metab 2015; 100: 453–457.
Buscemi S, Nicolucci A, Mattina A, Rosafio G, Massenti FM, Lucisano G et al. Association of dietary patterns with insulin resistance and clinically silent carotid atherosclerosis in apparently healthy people. Eur J Clin Nutr 2013; 67: 1284–1290.
Buscemi S, Geraci G, Massenti FM, Buscemi C, Costa F, D’Orio C et al. Renal function and carotid atherosclerosis in adults with no known kidney disease. Nutr Metab Cardiovasc Dis 2017; 27: 267–273.
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37: S81–S90.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–1645.
Waist Circumference and Waist–Hip Ratio: Report of a WHO Expert Consultation Geneva, 8–11 December 2008. Available at: http://apps.who.int/iris/bitstream/10665/44583/1/9789241501491_eng.pdf.
Buscemi S, Blunda G, Maneri R, Verga S . Bioelectrical characteristics of type 1 and type 2 diabetic subjects with reference to body water compartments. Acta Diabetol 1998; 35: 220–223.
Goff Jr DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R et al2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation 2014; 129: S49–S73.
Friedewald WT, Levy RI, Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.
Qiu S, Cai X, Sun Z, Schumann U, Zügel M, Steinacker JM . Chronic exercise training and circulating irisin in adults: a meta-analysis. Sports Med 2015; 45: 1577–1588.
Hecksteden A, Wegmann M, Steffen A, Kraushaar J, Morsch A, Ruppenthal S et al. Irisin and exercise training in humans - results from a randomized controlled training trial. BMC Med 2013; 11: 235.
Blüher S, Panagiotou G, Petroff D, Markert J, Wagner A, Klemm T et al. Effects of a 1-year exercise and lifestyle intervention on irisin, adipokines, and inflammatory markers in obese children. Obesity 2014; 22: 1701–1708.
Lee P, Linderman JD, Smith S, Brychta RJ, Wang J, Idelson C et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab 2014; 19: 302–309.
Daskalopoulou SS, Cooke AB, Gomez YH, Mutter AF, Filippaios A, Mesfum ET et al. Plasma irisin levels progressively increase in response to increasing exercise workloads in young, healthy, active subjects. Eur J Endocrinol 2014; 171: 343–352.
Fukushima Y, Kurose S, Shinno H, Cao Thi Thu H, Tamanoi A, Tsutsumi H et al. Relationships between serum irisin levels and metabolic parameters in Japanese patients with obesity. Obes Sci Pract 2016; 2: 203–209.
Zhang Y, Xie C, Wang H, Foss RM, Clare M, George EV et al. Irisin exerts dual effects on browning and adipogenesis of human white adipocytes. Am J Physiol Endocrinol Metab 2016; 311: E530–E541.
Roca-Rivada A, Castelao C, Senin LL, Landrove MO, Baltar J, Belén Crujeiras A et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One 2013; 8: e60563.
van den Beukel JC, Grefhorst A, Hoogduijn MJ, Steenbergen J, Mastroberardino PG, FJMF Dor et al. Women have more potential to induce browning of perirenal adipose tissue than men. Obesity 2015; 23: 1671–1679.
Sidebottom AC, Brown JE, Jacobs DR Jr . Pregnancy-related changes in body fat. Eur J Obstet Gynecol Reprod Biol 2001; 94: 216–223.
Sohlström A, Forsum E . Changes in adipose tissue volume and distribution during reproduction in Swedish women as assessed by magnetic resonance imaging. Am J Clin Nutr 1995; 61: 287–295.
Chen J, Huang Y, Gudson A, Qu S . Irisin: a new molecular marker and target in metabolic disorders. Lipids Health Dis 2015; 14: 2.
Sesti G, Andreozzi F, Fiorentino TV, Mannino GC, Sciacqua A, Marini MA et al. High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetol 2014; 51: 705–713.
Petersen AM, Pedersen BK . The anti-inflammatory effect of exercise. J Appl Physiol 2005; 98: 1154–1162.
Matsuo Y, Gleitsmann K, Mangner N, Werner S, Fischer T, Bowen TS et al. Fibronectin type III domain containing 5 expression in skeletal muscle in chronic heart failure-relevance of inflammatory cytokines. J Cachexia Sarcopenia Muscle 2015; 6: 62–72.
Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY et al. Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. Mol Cell 2001; 8: 971–982.
Colaianni G, Cuscito C, Mongelli T, Pignataro P, Buccoliero C, Liu P et al. The myokine irisin increases cortical bone mass. Proc Natl Acad Sci USA 2015; 112: 12157–121662.
Colaianni G, Mongelli T, Cuscito C, Pignataro P, Lippo L, Spiro G et al. Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice. Sci Rep 2017; 7: 2811.
Erickson HP . Irisin and FNDC5 in retrospect: An exercise hormone or a transmembrane receptor? Adipocyte 2013; 2: 289–293.
Albrecht E, Norheim F, Thiede B, Holen T, Ohashi T, Schering L et al. Irisin - a myth rather than an exercise-inducible myokine. Sci Rep 2015; 5: 8889.
Acknowledgements
We are gratefully indebted with Dr Antonio Nicolucci biostatistician, head of the Center for Outcomes Research and Clinical Epidemiology—CORESEARCH; Pescara, Italy (https://www.coresearch.it), for his precious advice and supervision of the statistical analyses.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on International Journal of Obesity website
Supplementary information
Rights and permissions
About this article
Cite this article
Buscemi, S., Corleo, D., Vasto, S. et al. Factors associated with circulating concentrations of irisin in the general population cohort of the ABCD study. Int J Obes 42, 398–404 (2018). https://doi.org/10.1038/ijo.2017.255
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2017.255
This article is cited by
-
Factors associated with body weight gain and insulin-resistance: a longitudinal study
Nutrition & Diabetes (2024)
-
Il muscolo come organo endocrino: focus su irisina
L'Endocrinologo (2022)
-
Cardiometabolic health, visceral fat and circulating irisin levels: results from a real-world weight loss study
Journal of Endocrinological Investigation (2021)
-
The association of circulating irisin with metabolic risk factors in Chinese adults: a cross-sectional community-based study
BMC Endocrine Disorders (2019)
-
Serum Irisin, Adropin, and Preptin in Obese Patients 6 Months After Bariatric Surgery
Obesity Surgery (2019)